276 related articles for article (PubMed ID: 26890144)
1. Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation.
Blondel S; Egesipe AL; Picardi P; Jaskowiak AL; Notarnicola M; Ragot J; Tournois J; Le Corf A; Brinon B; Poydenot P; Georges P; Navarro C; Pitrez PR; Ferreira L; Bollot G; Bauvais C; Laustriat D; Mejat A; De Sandre-Giovannoli A; Levy N; Bifulco M; Peschanski M; Nissan X
Cell Death Dis; 2016 Feb; 7(2):e2105. PubMed ID: 26890144
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
3. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
4. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
Wang Y; Ostlund C; Worman HJ
Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
[TBL] [Abstract][Full Text] [Related]
5. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
[TBL] [Abstract][Full Text] [Related]
6. Genetic and pharmacological modulation of lamin A farnesylation determines its function and turnover.
Foo MXR; Ong PF; Yap ZX; Maric M; Bong CJS; Dröge P; Burke B; Dreesen O
Aging Cell; 2024 May; 23(5):e14105. PubMed ID: 38504487
[TBL] [Abstract][Full Text] [Related]
7. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.
Wang Y; Ostlund C; Choi JC; Swayne TC; Gundersen GG; Worman HJ
Nucleus; 2012; 3(5):452-62. PubMed ID: 22895092
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
Mallampalli MP; Huyer G; Bendale P; Gelb MH; Michaelis S
Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14416-21. PubMed ID: 16186497
[TBL] [Abstract][Full Text] [Related]
9. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
[TBL] [Abstract][Full Text] [Related]
10. N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A.
Bifulco M; D'Alessandro A; Paladino S; Malfitano AM; Notarnicola M; Caruso MG; Laezza C
FEBS J; 2013 Dec; 280(23):6223-32. PubMed ID: 24112551
[TBL] [Abstract][Full Text] [Related]
11. A lamin A protein isoform overexpressed in Hutchinson-Gilford progeria syndrome interferes with mitosis in progeria and normal cells.
Cao K; Capell BC; Erdos MR; Djabali K; Collins FS
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):4949-54. PubMed ID: 17360355
[TBL] [Abstract][Full Text] [Related]
12. Pluripotent stem cells to model Hutchinson-Gilford progeria syndrome (HGPS): Current trends and future perspectives for drug discovery.
Lo Cicero A; Nissan X
Ageing Res Rev; 2015 Nov; 24(Pt B):343-8. PubMed ID: 26474742
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
14. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
15. Permanent farnesylation of lamin A mutants linked to progeria impairs its phosphorylation at serine 22 during interphase.
Moiseeva O; Lopes-Paciencia S; Huot G; Lessard F; Ferbeyre G
Aging (Albany NY); 2016 Feb; 8(2):366-81. PubMed ID: 26922519
[TBL] [Abstract][Full Text] [Related]
16. Lamin A-linked progerias: is farnesylation the be all and end all?
Smallwood DT; Shackleton S
Biochem Soc Trans; 2010 Feb; 38(Pt 1):281-6. PubMed ID: 20074075
[TBL] [Abstract][Full Text] [Related]
17. Quantification of Farnesylated Progerin in Hutchinson-Gilford Progeria Patient Cells by Mass Spectrometry.
Camafeita E; Jorge I; Rivera-Torres J; Andrés V; Vázquez J
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233036
[TBL] [Abstract][Full Text] [Related]
18. Diminished Canonical β-Catenin Signaling During Osteoblast Differentiation Contributes to Osteopenia in Progeria.
Choi JY; Lai JK; Xiong ZM; Ren M; Moorer MC; Stains JP; Cao K
J Bone Miner Res; 2018 Nov; 33(11):2059-2070. PubMed ID: 30001457
[TBL] [Abstract][Full Text] [Related]
19. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
McClintock D; Gordon LB; Djabali K
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
[TBL] [Abstract][Full Text] [Related]
20. Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition.
Marji J; O'Donoghue SI; McClintock D; Satagopam VP; Schneider R; Ratner D; Worman HJ; Gordon LB; Djabali K
PLoS One; 2010 Jun; 5(6):e11132. PubMed ID: 20559568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
